CTI Biopharma Corp CTIC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/24/21 EDT
3.04UNCH (UNCH)
Volume
1,752
Close
3.04quote price arrow down-0.01 (-0.33%)
Volume
449,761
52 week range
1.00 - 4.13
Loading...
  • Open3.07
  • Day High3.07
  • Day Low3.02
  • Prev Close3.05
  • 52 Week High4.13
  • 52 Week High Date03/22/21
  • 52 Week Low1.00
  • 52 Week Low Date09/25/20

Key Stats

  • Market Cap283.66M
  • Shares Out93.31M
  • 10 Day Average Volume0.61M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change-5.59

KEY STATS

  • Open3.07
  • Day High3.07
  • Day Low3.02
  • Prev Close3.05
  • 52 Week High4.13
  • 52 Week High Date03/22/21
  • 52 Week Low1.00
  • 52 Week Low Date09/25/20
  • Market Cap283.66M
  • Shares Out93.31M
  • 10 Day Average Volume0.61M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change-5.59

RATIOS/PROFITABILITY

  • EPS (TTM)-0.80
  • P/E (TTM)-3.82
  • Fwd P/E (NTM)-5.89
  • EBITDA (MRQ)-61.889M
  • ROE (MRQ)-106.61%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)80.74%
  • Net Margin (MRQ)-1,940.54%
  • Debt To Equity (MRQ)3.32%

EVENTS

  • Earnings Date11/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On CTI Biopharma Corp

There is no recent news for this security.

Profile

MORE
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult...
Laurent Fischer M.D.
Non-Executive Chairman
Adam Craig M.D., Ph.D.
President
Bruce Seeley
Chief Operating Officer
David Kirske
Chief Financial Officer
Address
3101 Western Ave Ste 800
Seattle, WA
98121-3017
United States

Top Peers

SYMBOLLASTCHG%CHG
INZY
Inozyme Pharma Inc
13.10-0.26-1.95%
INMB
INmune Bio Inc
20.14+0.79+4.08%
CKPT
Checkpoint Therapeutics Inc
3.37-0.16-4.53%
AVRO
AVROBIO Inc
5.98-0.27-4.32%
CRDF
Cardiff Oncology Inc
7.36+0.09+1.24%